Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus

European Journal of Immunology

Volumn 45, Issue 2, 2015, Pages 624-635

  Fossum, Even ^a   Grødeland, Gunnveig ^a   Terhorst, Dorothea ^b,c,d   Tveita, Anders A ^a   Vikse, Elisabeth ^a   Mjaaland, Siri ^a,e   Henri, Sandrine ^c   Malissen, Bernard ^c   Bogen, Bjarne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^d INSERM   (France)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

CD8+ T cell responses; Dendritic cells; Influenza; Vaccine; Xcr1

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G2A ANTIBODY; INFLUENZA VACCINE; UNCLASSIFIED DRUG; XCL1 HEMAGGLUTININ FUSION PROTEIN; XCL1 OVALBUMIN FUSION PROTEIN; CHEMOKINE RECEPTOR; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; IMMUNOGLOBULIN G; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; XC CHEMOKINE RECEPTOR 1, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; IMMUNE RESPONSE; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELLULAR IMMUNITY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE INFECTIONS; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CELL PROLIFERATION; CROSS-PRIMING; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; HEK293 CELLS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; ORTHOMYXOVIRIDAE INFECTIONS; RECEPTORS, CHEMOKINE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 84923103556     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201445080     Document Type: Article

References (43)

1. Moore, M. W., Carbone, F. R. and Bevan, M. J., Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988. 54: 777-785.
2. Pooley, J. L., Heath, W. R. and Shortman, K., Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8 +dendritic cells. J. Immunol. 2001. 166: 5327-5330.
3. den Haan, J. M., Lehar, S. M. and Bevan, M. J., CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 2000. 192: 1685-1696.
4. Keler, T., He, L., Ramakrishna, V. and Champion, B., Antibody-targeted vaccines. Oncogene 2007. 26: 3758-3767.
5. Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M. C. and Steinman, R. M., Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 2002. 196: 1627-1638.
6. Sancho, D., Mourao-Sa, D., Joffre, O. P., Schulz, O., Rogers, N. C., Pennington, D. J., Carlyle, J. R. et al., Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 2008. 118: 2098-2110.
7. Caminschi, I., Proietto, A. I., Ahmet, F., Kitsoulis, S., Shin Teh, J., Lo, J. C., Rizzitelli, A. et al., The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 2008. 112: 3264-3273.
8. Witmer-Pack, M. D., Swiggard, W. J., Mirza, A., Inaba, K. and Steinman, R. M., Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues. Cell Immunol. 1995. 163: 157-162.
9. Inaba, K., Swiggard, W. J., Inaba, M., Meltzer, J., Mirza, A., Sasagawa, T., Nussenzweig, M. C. et al., Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol. 1995. 163: 148-156.
10. Schraml, B. U., van Blijswijk, J., Zelenay, S., Whitney, P. G., Filby, A., Acton, S. E., Rogers, N. C. et al., Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage. Cell 2013. 154: 843-858.
11. Dorner, B. G., Dorner, M. B., Zhou, X., Opitz, C., Mora, A., Guttler, S., Hutloff, A. et al., Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity 2009. 31: 823-833.
12. Crozat, K., Tamoutounour, S., Vu Manh, T. P., Fossum, E., Luche, H., Ardouin, L., Guilliams, M. et al., Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8{alpha} +type. J. Immunol. 2011. 187: 4411-4415.
13. Bachem, A., Guttler, S., Hartung, E., Ebstein, F., Schaefer, M., Tannert, A., Salama, A. et al., Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141 +cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 2010. 207: 1273-1281.
14. Crozat, K., Guiton, R., Contreras, V., Feuillet, V., Dutertre, C. A., Ventre, E., Vu Manh, T. P. et al., The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha +dendritic cells. J. Exp. Med. 2010. 207: 1283-1292.
15. Haniffa, M., Shin, A., Bigley, V., McGovern, N., Teo, P., See, P., Wasan, P. S. et al., Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 2012. 37: 60-73.
16. Dutertre, C. A., Jourdain, J. P., Rancez, M., Amraoui, S., Fossum, E., Bogen, B., Sanchez, C. et al., TLR3-responsive, XCR1+, CD141(BDCA-3)+/CD8alpha+-equivalent dendritic cells uncovered in healthy and simian immunodeficiency virus-infected rhesus macaques. J. Immunol. 2014. 192: 4697-4708.
17. Contreras, V., Urien, C., Guiton, R., Alexandre, Y., Vu Manh, T. P., Andrieu, T., Crozat, K. et al., Existence of CD8alpha-like dendritic cells with a conserved functional specialization and a common molecular signature in distant mammalian species. J. Immunol. 2010. 185: 3313-3325.
18. Kawamura, H. and Berzofsky, J. A., Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J. Immunol. 1986. 136: 58-65.
19. Baier, G., Baier-Bitterlich, G., Looney, D. J. and Altman, A., Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro. J. Virol. 1995. 69: 2357-2365.
20. Lunde, E., Munthe, L. A., Vabo, A., Sandlie, I. and Bogen, B., Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat. Biotechnol. 1999. 17: 670-675.
21. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V. et al., Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001. 194: 769-779.
22. Biragyn, A., Tani, K., Grimm, M. C., Weeks, S. and Kwak, L. W., Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 1999. 17: 253-258.
23. Fredriksen, A. B. and Bogen, B., Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood 2007. 110: 1797-1805.
24. Ruffini, P. A., Grodeland, G., Fredriksen, A. B. and Bogen, B., Human chemokine MIP1alpha increases efficiency of targeted DNA fusion vaccines. Vaccine 2010. 29: 191-199.
25. Oynebraten, I., Lovas, T. O., Thompson, K. and Bogen, B., Generation of antibody-producing hybridomas following one single immunization with a targeted DNA vaccine. Scand. J. Immunol. 2012. 75: 379-388.
26. Kuloglu, E. S., McCaslin, D. R., Kitabwalla, M., Pauza, C. D., Markley, J. L. and Volkman, B. F., Monomeric solution structure of the prototypical "C" chemokine lymphotactin. Biochemistry 2001. 40: 12486-12496.
27. Grodeland, G., Mjaaland, S., Roux, K. H., Fredriksen, A. B. and Bogen, B., DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J. Immunol. 2013. 191: 3221-3231.
28. Kataoka, T., Shinohara, N., Takayama, H., Takaku, K., Kondo, S., Yonehara, S. and Nagai, K., Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 1996. 156: 3678-3686.
29. Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C. et al., Differential antigen processing by dendritic cell subsets in vivo. Science 2007. 315: 107-111.
30. Schiavo, R., Baatar, D., Olkhanud, P., Indig, F. E., Restifo, N., Taub, D. and Biragyn, A., Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006. 107: 4597-4605.
31. Park, H. Y., Light, A., Lahoud, M. H., Caminschi, I., Tarlinton, D. M. and Shortman, K., Evolution of B cell responses to Clec9A-targeted antigen. J. Immunol. 2013. 191: 4919-4925.
32. Nchinda, G., Kuroiwa, J., Oks, M., Trumpfheller, C., Park, C. G., Huang, Y., Hannaman, D. et al., The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 2008. 118: 1427-1436.
33. Dorner, B. G., Scheffold, A., Rolph, M. S., Huser, M. B., Kaufmann, S. H., Radbruch, A., Flesch, I. E. et al., MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc. Natl. Acad. Sci. USA 2002. 99: 6181-6186.
34. Nimmerjahn, F., Bruhns, P., Horiuchi, K. and Ravetch, J. V., FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005. 23: 41-51.
35. Dilillo, D. J., Tan, G. S., Palese, P. and Ravetch, J. V., Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 2014. 20: 143-151.
36. Schmitz, N., Beerli, R. R., Bauer, M., Jegerlehner, A., Dietmeier, K., Maudrich, M., Pumpens, P. et al., Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur. J. Immunol. 2012. 42: 863-869.
37. Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J. and Carbone, F. R., T cell receptor antagonist peptides induce positive selection. Cell 1994. 76: 17-27.
38. Barnden, M. J., Allison, J., Heath, W. R. and Carbone, F. R., Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 1998. 76: 34-40.
39. Fredriksen, A. B., Sandlie, I. and Bogen, B., DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol. Ther. 2006. 13: 776-785.
40. Norderhaug, L., Olafsen, T., Michaelsen, T. E. and Sandlie, I., Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J. Immunol. Methods 1997. 204: 77-87.
41. Henri, S., Poulin, L. F., Tamoutounour, S., Ardouin, L., Guilliams, M., de Bovis, B., Devilard, E. et al., CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J. Exp. Med. 2009. 207: 189-206.
42. Durward, M., Harms, J. and Splitter, G., Antigen specific killing assay using CFSE labeled target cells. J. Vis. Exp. 2010. 45: e2250.
43. Matzinger, P., The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods 1991. 145: 185-192.